Brief: Solid Biosciences To Showcase Proprietary Next-Generation Capsid AAV-SLB101 And Cardiac Gene Therapy Pipeline At The 22nd Global Cardiovascular Clinical Trialists Forum
08/12/2025 13:06
Dec 8 (Reuters) - Solid Biosciences Inc SLDB.O: SOLID BIOSCIENCES TO SHOWCASE PROPRIETARY NEXT-GENERATION CAPSID AAV-SLB101 AND CARDIAC GENE THERAPY PIPELINE AT THE 22ND GLOBAL CARDIOVASCULAR CLINICAL TRIALISTS (CVCT) FORUM Source text: ID:nGNX3cBdcB Further company coverage: SLDB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs